drugset
drugset / Trial / NCT03687736

Subject Satisfaction With AbobutulinumtoxinA Treatment

NCT03687736 ↗

Phase 4 Completed 120 enrolled Galderma R&D
NaSingle-groupOpen-labelOther

Summary

An interventional Phase 4 study to assess subject satisfaction with abobotulinumtoxinA treatment.

Timeline

Start
2018-10-02
Primary completion
2019-11-07
Completion
2019-12-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Botulinum toxin type A Protein / enzyme biologic — —

Indications

No indication recorded.